COMPOUND PROFILE / PEPTIDES & ANALOGUES
Elamipretide / SS-31.
Research draftElamipretide, also called SS-31, is a mitochondria-targeting tetrapeptide.
Research evidence and COA results do not establish suitability for use. This is educational information, not a dosing guide or personal medical advice.
Targeted source and identity review, not a systematic review or complete regulatory audit.
Overview
Elamipretide, also called SS-31, is a mitochondria-targeting tetrapeptide.
Mechanism
It binds cardiolipin in the inner mitochondrial membrane and affects mitochondrial structure and function.
Human research
It has disease-specific clinical research. FDA accelerated approval for Barth syndrome is based on a surrogate strength measure, with confirmatory research required.
Preclinical & other research
Laboratory and animal work investigated mitochondrial dysfunction across several disease models.
Safety & unknowns
Injection-site reactions and hypersensitivity are relevant. Disease-specific evidence does not establish general anti-ageing benefit.
Regulatory status
Forzinity received US accelerated approval for Barth syndrome in patients weighing at least 30 kg; this does not approve unrelated research vials.
Reported use & evidence
The supplied Elamipretide / SS-31 profile and its cited sources are imported. Community experiences and laboratory evidence remain separate from these descriptions. Missing evidence is not a zero result.
Sources & references
Follow the cited records and registered research. Profiles remain research drafts.